Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.

You may also be interested in...



European Regulatory Round-Up: EMA And The UK Heed The Calls Of Industry; France Is Otherwise Occupied

The European Medicines Agency follows through on its transparency initiative with comprehensive list of products under review and also reduces pharmacovigilence data reporting requirements.

Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce

AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.

Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce

AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel